Top

Published in:

01-05-2018 | Clinical Study

Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study

Authors: Connor J. Kinslow, Samuel S. Bruce, Ali I. Rae, Sameer A. Sheth, Guy M. McKhann, Michael B. Sisti, Jeffrey N. Bruce, Adam M. Sonabend, Tony J. C. Wang

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

The World Health Organization (WHO) classification of tumors of the central nervous system (CNS) was recently updated, restructuring solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into one combined entity. This is the first population-based study to examine outcomes of SFT/HPC based on the new WHO guidelines. The Surveillance, Epidemiology, and End Results (SEER) database (1998–2013) was queried to examine age-adjusted incidence and prognostic factors associated with overall survival in 416 surgically resected cases. Age-adjusted incidence was calculated to be 3.77 per 10,000,000 and was rising. Median survival was 155 months, with 5- and 10-year survival rates of 78 and 61%, respectively. Younger age, Asian/Pacific Islander versus white race, benign histology, tumor location, gross-total resection (GTR), and GTR plus radiation (RT) versus subtotal resection were significantly associated with survival. In multivariable analysis, older age (HR = 1.038, p < 0.0001), infratentorial location (HR = 2.019, p = 0.038), GTR (HR = 0.313, p = 0.041), and GTR + RT (HR = 0.215, p = 0.008) were independent prognostic factors. In the HPC and borderline/malignant subgroups, GTR + RT was associated with significantly increased survival compared with GTR alone (HR = 0.537, p = 0.039 and HR = 0.525, p = 0.038). After eliminating patients that died within 3 months of diagnosis, GTR + RT was still associated with an incremental increase in survival (HR = 0.238, p = 0.031) over GTR alone (HR = 0.280, p = 0.054). GTR + RT may be optimal in the management CNS HPC and SFT/HPC tumors with borderline/malignant features. This study, in combination with existing literature, warrants further investigation of adjuvant radiation through a prospective clinical trial.

Available only for authorised users

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

Robinson DR, Wu Y-M, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung Y-S, Chen C-L, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta KJ, Kunju LP, Talpaz M, Mosquera JM, Singer S, Schuetze SM, Antonescu CR, Chinnaiyan AM (2013) Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet 45: 180–185. http://www.nature.com/ng/journal/v45/n2/abs/ng.2509.html-supplementary-information

Chmielecki J, Crago AM, Rosenberg M, O’Connor R, Walker SR, Ambrogio L, Auclair D, McKenna A, Heinrich MC, Frank DA, Meyerson M (2013) Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 45: 131–132. http://www.nature.com/ng/journal/v45/n2/abs/ng.2522.html-supplementary-information

Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Göck T, Jones DTW, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, König R, Wiestler OD, Pfister SM, von Deimling A (2013) Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 125:651–658. https://doi.org/10.1007/s00401-013-1117-6 CrossRefPubMed

Bouvier C, Metellus P, de Paula AM, Vasiljevic A, Jouvet A, Guyotat J, Mokhtari K, Varlet P, Dufour H, Figarella-Branger D (2012) Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol (Zurich) 22:511–521. https://doi.org/10.1111/j.1750-3639.2011.00552.x CrossRef

Macagno N, Figarella-Branger D, Mokthari K, Metellus P, Jouvet A, Vasiljevic A, Loundou A, Bouvier C (2016) Differential diagnosis of meningeal SFT-HPC and meningioma: which immunohistochemical markers should be used? Am J Surg Pathol 40:270–278. https://doi.org/10.1097/pas.0000000000000526 PubMed

Fritchie KJ, Jin L, Rubin BP, Burger PC, Jenkins SM, Barthelmess S, Moskalev EA, Haller F, Oliveira AM, Giannini C (2016) NAB2-STAT6 gene fusion in meningeal hemangiopericytoma and solitary fibrous tumor. J Neuropathol Exp Neurol 75:263–271. https://doi.org/10.1093/jnen/nlv026 CrossRefPubMed

Savary C, Rousselet MC, Michalak S, Fournier HD, Taris M, Loussouarn D, Rousseau A (2016) [Solitary fibrous tumors and hemangiopericytomas of the meninges: Immunophenotype and histoprognosis in a series of 17 cases]. Ann Pathol 36:258–267. https://doi.org/10.1016/j.annpat.2016.06.002 CrossRefPubMed

Fletcher CDM (2006) The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48:3–12. https://doi.org/10.1111/j.1365-2559.2005.02284.x CrossRefPubMed

10.

Yalcin CE, Tihan T (2016) Solitary fibrous tumor/hemangiopericytoma dichotomy revisited: a restless family of neoplasms in the CNS. Adv Anat Pathol 23:104–111. https://doi.org/10.1097/pap.0000000000000103 CrossRefPubMed

11.

Bisceglia M, Galliani C, Giannatempo G, Lauriola W, Bianco M, D’Angelo V, Pizzolitto S, Vita G, Pasquinelli G, Magro G, Dor DB (2011) Solitary fibrous tumor of the central nervous system: a 15-year literature survey of 220 cases (August 1996–July 2011). Adv Anat Pathol 18:356–392. https://doi.org/10.1097/PAP.0b013e318229c004 CrossRefPubMed

12.

Zeng L, Wang Y, Wang Y, Han L, Niu H, Zhang M, Ke C, Chen J, Lei T (2016) Analyses of prognosis-related factors of intracranial solitary fibrous tumors and hemangiopericytomas help understand the relationship between the two sorts of tumors. J Neuro-Oncol. https://doi.org/10.1007/s11060-016-2282-y

13.

Tihan T, Viglione M, Rosenblum MK, Olivi A, Burger PC (2003) Solitary fibrous tumors in the central nervous system. A clinicopathologic review of 18 cases and comparison to meningeal hemangiopericytomas. Arch Pathol Lab Med 127:432–439. https://doi.org/10.1043/0003-9985(2003)127003C0432:sftitc003E2.0.co;2 PubMed

14.

Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE (1991) Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 22:84–91CrossRefPubMed

15.

Kinslow CJ, Rajpara RS, Wu C-C, Bruce SS, Canoll PD, Wang S-H, Sonabend AM, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Wang TJC (2017) Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2450-8

16.

Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG (1989) Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25:514–522CrossRefPubMed

17.

Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2012) Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:1628–1636. https://doi.org/10.1002/cncr.26411 CrossRefPubMed

18.

Rutkowski MJ, Bloch O, Jian BJ, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2011) Management of recurrent intracranial hemangiopericytoma. J Clin Neurosci 18:1500–1504. https://doi.org/10.1016/j.jocn.2011.04.009 CrossRefPubMed

19.

Ambrosini-Spaltro A, Eusebi V (2010) Meningeal hemangiopericytomas and hemangiopericytoma/solitary fibrous tumors of extracranial soft tissues: a comparison. Virchows Archiv Int J Pathol 456:343–354. https://doi.org/10.1007/s00428-010-0888-6 CrossRef

20.

Mathieu D (2016) Why do hemangiopericytomas have such high recurrence rates? Expert Rev Anticancer Ther 16:1095–1096. https://doi.org/10.1080/14737140.2016.1237289 CrossRefPubMed

21.

Bastin KT, Mehta MP (1992) Meningeal hemangiopericytoma: defining the role for radiation therapy. J Neurooncol 14:277–287CrossRefPubMed

22.

Schiariti M, Goetz P, El-Maghraby H, Tailor J, Kitchen N (2011) Hemangiopericytoma: long-term outcome revisited. J Neurosurg 114:747–755. https://doi.org/10.3171/2010.6.JNS091660 CrossRefPubMed

23.

Ghose A, Guha G, Kundu R, Tew J, Chaudhary R (2014) CNS hemangiopericytoma: a systematic review of 523 patients. Am J Clin Oncol. https://doi.org/10.1097/coc.0000000000000146

24.

Carneiro SS, Scheithauer BW, Nascimento AG, Hirose T, Davis DH (1996) Solitary fibrous tumor of the meninges: a lesion distinct from fibrous meningioma. A clinicopathologic and immunohistochemical study. Am J Clin Oncol 106:217–224

25.

Stout AP, Murray MR (1942) Hemangiopericytoma: a vascular tumor featuring Zimmermann’s pericytes. Ann Surg 116:26–33CrossRefPubMedPubMedCentral

26.

Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol (Zurich) 3:255–268CrossRef

27.

Greenlee RT, Goodman MT, Lynch CF, Platz CE, Havener LA, Howe HL (2010) The occurrence of rare cancers in United States adults, 1995–2004. Public Health Rep 125: 28–43 (Washington, DC: 1974)CrossRefPubMedPubMedCentral

28.

Bilimoria KY, Stewart AK, Winchester DP, Ko CY (2008) The national cancer data base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683–690. https://doi.org/10.1245/s10434-007-9747-3 CrossRefPubMedPubMedCentral

29.

Warren JL, Harlan LC (2003) Can cancer registry data be used to study cancer treatment? Med Care 41:1003–1005. https://doi.org/10.1097/01.mlr.0000086827.00805.b5 CrossRefPubMed

30.

(released April 2016, based on the November 2015 submission) Surveillance, Epidemiology,and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence- SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) < Katrina/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969–2014 Counties.

31.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. https://doi.org/10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

32.

Ghia AJ, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery 72:203–209. https://doi.org/10.1227/NEU.0b013e31827b9e68 CrossRefPubMed

33.

Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI, Bruce JN (2014) The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg 120:300–308. https://doi.org/10.3171/2013.10.jns13113 CrossRefPubMed

34.

Stessin AM, Sison C, Nieto J, Raifu M, Li B (2013) The role of postoperative radiation therapy in the treatment of meningeal hemangiopericytoma—Experience from the SEER database. Int J Radiat Oncol Biol Phys 85:784–790. https://doi.org/10.1016/j.ijrobp.2012.05.042 CrossRefPubMed

35.

Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL (2016) Comparison of SEER treatment data with medicare claims. Med Care 54:e55–e64. https://doi.org/10.1097/mlr.0000000000000073 CrossRef

36.

Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, Mills SA, Barani IJ, Parsa AT (2010) Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg 113:333–339. https://doi.org/10.3171/2010.3.jns091882 CrossRefPubMed

37.

Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH (2004) Intracranial meningeal hemangiopericytoma: the role of radiotherapy. Cancer 100:1491–1497. https://doi.org/10.1002/cncr.20109 CrossRefPubMed

38.

Ramakrishna R, Rostomily R, Sekhar L, Rockhill J, Ferreira M (2014) Hemangiopericytoma: radical resection remains the cornerstone of therapy. J Clin Neurosci 21:612–615. https://doi.org/10.1016/j.jocn.2013.08.006 CrossRefPubMed

39.

Kim JH, Jung HW, Kim YS, Kim CJ, Hwang SK, Paek SH, Kim DG, Kwun BD (2003) Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol 59:47–53 (discussion 53–44)CrossRefPubMed

40.

Lee EJ, Kim JH, Park ES, Khang SK, Cho YH, Hong SH, Kim CJ (2016) The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma. J Neuro-Oncol 127:181–190. https://doi.org/10.1007/s11060-015-2030-8 CrossRef

41.

Chen L-f, Yang Y, Yu X-g, Gui Q-p, Xu B-n, Zhou D-b (2015) Multimodal treatment and management strategies for intracranial hemangiopericytoma. J Clin Neurosci 22:718–725. https://doi.org/10.1016/j.jocn.2014.11.011 CrossRefPubMed

42.

Choi J, Park S-H, Khang SK, Suh Y-L, Kim SP, Lee YS, Kwon HS, Kang S-G, Kim SH (2016) Hemangiopericytomas in the central nervous system: a Multicenter Study of Korean Cases with validation of the usage of STAT6 immunohistochemistry for diagnosis of disease. Ann Surg Oncol. https://doi.org/10.1245/s10434-016-5414-x

43.

Zhang GJ, Wu Z, Zhang LW, Li D, Zhang JT (2017) Surgical management and adverse factors for recurrence and long-term survival in hemangiopericytoma patients. World Neurosurg. https://doi.org/10.1016/j.wneu.2017.05.010

44.

Staples JJ, Robinson RA, Wen BC, Hussey DH (1990) Hemangiopericytoma—The role of radiotherapy. Int J Radiat Oncol Biol Phys 19:445–451. https://doi.org/10.1089/ten.2005.11.985 CrossRefPubMed

45.

Ghia AJ, Chang EL, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD (2013) Intracranial hemangiopericytoma: patterns of failure and the role of radiation therapy. Neurosurgery 73:624–630. https://doi.org/10.1227/neu.0000000000000064 (discussion 630–621)CrossRefPubMed

46.

Zhu H, Duran D, Hua L, Tang H, Chen H, Zhong P, Zheng K, Wang Y, Che X, Bao W, Wang Y, Xie Q, Gong Y (2016) Prognostic factors in patients with primary hemangiopericytomas of the central nervous system: a series of 103 cases at a single institution. World Neurosurg 90:414–419. https://doi.org/10.1016/j.wneu.2016.02.103 CrossRefPubMed

47.

Dufour H, Metellus P, Fuentes S, Murracciole X, Regis J, Figarella-Branger D, Grisoli F (2001) Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 48:756–762 (discussion 762–753)PubMed

48.

Caldarella A, Crocetti E, Paci E (2011) Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neuro-Oncol 104:589–594. https://doi.org/10.1007/s11060-011-0533-5 CrossRef

49.

Suissa S (2008) Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167:492–499. https://doi.org/10.1093/aje/kwm324 CrossRefPubMed

Title: Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study
Authors: Connor J. Kinslow
Samuel S. Bruce
Ali I. Rae
Sameer A. Sheth
Guy M. McKhann
Michael B. Sisti
Jeffrey N. Bruce
Adam M. Sonabend
Tony J. C. Wang
Publication date: 01-05-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2787-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Renin angiotensin system and its role in biomarkers and treatment in gliomas

Surgical treatment of glioblastoma in the elderly: the impact of complications

High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin

Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery

Letter to the editor: local alkylating chemotherapy applied immediately after 5-ALA guided resection of glioblastoma does not provide additional benefit